Motilak pills 10mg №30

Motilak/Motilak

Composition and release form

Motilak - coated tablets: 1 table. contains Domperidone 10 mg; excipients: potato starch; lactose; MCC; aerosil; polyvinylpyrrolidone; Magnesium stearate; sodium carboxymethyl starch; hydroxypropylcellulose; twin 80; titanium dioxide; colloidal silicon dioxide; in packing of 10 and 30 pieces;

Motilak - pills for sucking: 1 table. contains domperidone 10 mg; in packing of 10 and 30 pieces.

Farmbutcologic action

Motilak has an antiemetic, prokinetic effect.

Indications

A complex of dyspeptic symptoms, often associated with delayed gastric emptying, gastroesophageal reflux, esophagitis;

- feeling of fullness in the epigastrium, feeling of bloating, pain in the upper abdomen;

- belching, flatulence;

- heartburn with or without reflux of the contents of the stomach into the oral cavity.

Nausea and vomiting of functional, organic, infectious origin, caused by radiotherapy, drug therapy or dietary disorders. A specific indication is nausea and vomiting caused by dopamine agonists when used in Parkinson’s disease (such as L-dopa and bromocriptine).

Contraindications

Motilak is contraindicated in patients with established intolerance to the drug.

Motilak should not be used when stimulation of the motor function of the stomach can be dangerous, i.e. with Gastrointestinal bleeding, mechanical obstruction or perforation. Motilak is also contraindicated in patients with prolactin-secreting pituitary tumor (prolactinoma).

Use during pregnancy and lactation

With the introduction of animals in doses up to 160 mg / kg / day does not have a teratogenic effect. The use of Motilak in the first trimester of pregnancy is possible if the expected effect of therapy outweighs the potential risk to the fetus. Currently, there is no evidence of an increased risk of malformations in humans. In women, domperidone concentrations in breast milk are 4 times lower than corresponding plasma concentrations. It is not known whether this level has a negative effect on newborns. Therefore, if the mother takes Motilak, breastfeeding is not recommended, unless the expected benefit justifies the potential risk.

Side effects

Side effects are rare. There have been exceptional cases of transient bowel spasms. Extrapyramidal effects are rarely observed in children and are an exception for adults. These phenomena are completely reversible and spontaneously disappear after cessation of treatment.

Since the pituitary gland is outside the BBB, Motilak can induce an increase in the level of prolactin in the plasma. In rare cases, this hyperprolactinemia can stimulate the appearance of galactorrhea and gynecomastia.

There have been rare allergic reactions, such as rashes and urticaria.

Dosage and administration

Motilak take orally, for 15-20 minutes before eating.

Adults in cases of acute nausea or vomiting: 20 mg 3-4 times a day and at bedtime.

In chronic dyspeptic conditions: 10 mg (1 tab.) 3-4 times a day and, if necessary, at bedtime. If necessary, double the indicated dose.

Patients with severe impaired renal function when reappointed, the multiplicity of intake should not exceed 1-2 times a day, it may be necessary to reduce the dose of the drug (depending on the severity of insufficiency).

Storage conditions and shelf life

In a dry, dark place at room temperature no higher than 25 ° C. Shelf life - 2 years.